인플레이션 장비 : 시장 점유율 분석, 산업 동향, 통계, 성장 예측(2025-2030년)

The Inflation devices market size stands at USD 643.48 million in 2025 and is forecast to reach USD 835.04 million by 2030, expanding at a 5.35% CAGR over the period.

This outlook demonstrates the ability of the Inflation devices market to adapt to aging-population pressures, a heavier cardiovascular disease burden, and the rapid shift of catheter procedures into outpatient settings. Persistently high shipping, labor, and raw-material expenses-exacerbated by geopolitical tensions-compel manufacturers to re-engineer logistics footprints and invest 3-5% of revenue in supply-chain services. At the same time, digital pressure-sensing consoles are moving from optional add-ons to mandatory procurement criteria as providers chase data for quality metrics, while ambulatory surgical centers (ASCs) expand procedure volumes on the back of Medicare's USD 6.8 billion spend in 2023, representing an 11.5% increase from the previous year's USD 6.1 billion Medicare Payment Advisory Commission.

Global Inflation Devices Market Trends and Insights

Rising prevalence of cardiovascular & peripheral arterial diseases

Ischemic-heart-disease patients in the United States are projected to top 29 million by 2060. This demographic surge underpins recurrent demand in the Inflation devices market, particularly for units rated 15-30 atm that now satisfy 58.27% of global requirement. Hospitals are scaling cath-lab capacity and choosing pumps that offer granular pressure control and temperature-stable gauges, positioning suppliers with robust, intuitive designs to win high-value contracts in aging economies.

Growth in minimally-invasive angioplasty procedures

FDA clearance of the AGENT Paclitaxel-Coated Balloon Catheter, which cut major adverse events 11.1% at 12 months, illustrates innovation's role in expanding case volumes. ASCs, buoyed by double-digit Medicare spending growth, prioritize rapid device setup and digital monitoring. In response, manufacturers of the Inflation devices market roll out consoles with auto-inflation algorithms to streamline same-day discharge protocols.

High average selling price of digital inflation devices

Digital consoles list 30-40% higher than analog pumps, limiting uptake where hospital margins remain thin. Cost-of-ownership assessments-which include calibration, software, and training-may widen that gap. Analogue pumps therefore persist in emergency carts, tempering growth in the premium tier of the Inflation devices market.

Other drivers and restraints analyzed in the detailed report include:

1. Favourable reimbursement reforms for catheter-based interventions
2. Integration of digital pressure-sensing & data logging
3. Stringent Class III regulatory pathway in key markets

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Analog pumps generated 62.67% of the Inflation devices market in 2024, favored for reliability and low unit cost. High-volume hospitals continue to buy analog because technicians already master the workflow. Still, digital devices are projected to add USD 122 million by 2030 on a 6.24% CAGR as centers seek audit-ready data capture. Wireless consoles that log every inflation-deflation cycle satisfy accreditation mandates, raising switching incentives inside the Inflation devices market.

Digital systems integrate pressure graphs, auto-adjust algorithms, and remote diagnostics, slashing biomedical engineer call-outs. Trade-in credits and leasing plans dilute sticker shock, enabling independent ASCs to leapfrog older technology. Although analog remains entrenched, the strategic direction inside the Inflation devices market points to data-centric platforms becoming the reference standard.

Coronary angioplasty still dominates volume, but neurovascular interventions register the fastest CAGR at 6.46%. Micro-profile pumps capable of fractional-atmosphere increments are in high demand among neuro-interventionalists, highlighting the expanding technical sophistication of the Inflation devices market.

Peripheral angioplasty enjoys steady patient inflow as awareness of critical-limb ischemia spreads. Gastroenterologists report an 88.9% success rate using drug-coated balloons for benign esophageal strictures, encouraging GI units to stock dedicated inflation kits. Urologists engaged in prostate-artery embolization likewise recruit ultra-high-resolution imaging that benefits from pressure-stable devices. Combined, these applications enlarge the procedurally diverse base of the Inflation devices market.

The Inflation Devices Market Report is Segmented by Product Type (Analog Inflation Devices, Digital Inflation Devices), Pressure Range (less Than 15 Atm, 15 - 30 Atm, More Than 30 Atm), Application (Coronary Angioplasty, Peripheral Angioplasty, and More), End User (Hospitals, Ambulatory Surgical Centers, and More, and Geography (North America, Europe, and More). The Market Forecasts are Provided in Terms of Value (USD).

Geography Analysis

North America generated 42.23% of global revenue in 2024, underpinned by high procedural density and supportive reimbursement. CMS's 2.93% fee-schedule uplift secures predictable returns for providers, fueling capital expenditure on next-generation consoles. Canadian labs, benefiting from device reciprocity with FDA approvals, follow U.S. buying patterns, while Mexico upgrades cardiac infrastructure through public-private funding.

Europe maintains second position through comprehensive insurance coverage and stringent MDR oversight, which elevates demand for pumps with exportable log files. Germany, France, and the United Kingdom together perform more than 600,000 PCI and peripheral procedures per year, guaranteeing baseline throughput for the Inflation devices market. Southern Europe, seeking cost balance, often opts for hybrid analog-digital configurations that meet compliance at lower capital cost.

Asia-Pacific is forecast to expand 7.18% annually, the sharpest pace in the Inflation devices market. China approved 12,213 medical devices in 2023, over half in Class III, reflecting regulator willingness to fast-track innovation. India's domestic manufacturing push is narrowing import gaps, opening sub-USD 2,000 analog segments. Japan and South Korea, both aging rapidly, sustain complex neurovascular case growth, creating premium device pockets. Southeast Asian governments co-finance cath-lab rollouts, enabling first-time purchases and widening regional demand for the Inflation devices market.

1. Merit Medical Systems
2. Cook Group
3. B. Braun
4. Terumo
5. Boston Scientific
6. Medtronic
7. Abbott Laboratories
8. Teleflex
9. Atrion Corporation
10. Argon Medical Devices
11. Cardinal Health
12. Penumbra
13. Nipro
14. Olympus
15. Smiths Group
16. Shenzhen SCW Medicath Ltd.
17. Lepu Medical
18. Integra LifeSciences
19. Acandis

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising prevalence of cardiovascular & peripheral arterial diseases
  • 4.2.2 Growth in minimally-invasive angioplasty procedures
  • 4.2.3 Favourable reimbursement reforms for catheter-based interventions
  • 4.2.4 Integration of digital pressure-sensing & data logging in inflation devices
  • 4.2.5 Adoption in neurovascular & structural-heart interventions
  • 4.2.6 Shift toward single-use sterile inflation devices for infection control
• 4.3 Market Restraints
  • 4.3.1 High average selling price of digital inflation devices
  • 4.3.2 Stringent Class III regulatory pathway in key markets
  • 4.3.3 Supply-chain vulnerability for precision pressure gauges & syringes
  • 4.3.4 Growing catheter designs that eliminate separate inflation devices
• 4.4 Value / Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Bargaining Power of Buyers
  • 4.7.3 Bargaining Power of Suppliers
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Competitive Rivalry

5 Market Size & Growth Forecasts

• 5.1 By Product Type (Value)
  • 5.1.1 Analog Inflation Devices
  • 5.1.2 Digital Inflation Devices
• 5.2 By Pressure Range (Value)
  • 5.2.1 less than 15 atm
  • 5.2.2 15 - 30 atm
  • 5.2.3 more than 30 atm
• 5.3 By Application (Value)
  • 5.3.1 Coronary Angioplasty
  • 5.3.2 Peripheral Angioplasty
  • 5.3.3 Neurovascular Procedures
  • 5.3.4 Gastroenterology & ERCP
  • 5.3.5 Urology & Others
• 5.4 By End User (Value)
  • 5.4.1 Hospitals
  • 5.4.2 Ambulatory Surgical Centers
  • 5.4.3 Specialty Clinics & Cath Labs
• 5.5 By Geography (Value)
  • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
  • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
  • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 India
    • 5.5.3.3 Japan
    • 5.5.3.4 South Korea
    • 5.5.3.5 Australia
    • 5.5.3.6 Rest of Asia-Pacific
  • 5.5.4 South America
    • 5.5.4.1 Brazil
    • 5.5.4.2 Argentina
    • 5.5.4.3 Rest of South America
  • 5.5.5 Middle East and Africa
    • 5.5.5.1 GCC
    • 5.5.5.2 South Africa
    • 5.5.5.3 Rest of Middle East and Africa

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
  • 6.3.1 Merit Medical Systems Inc.
  • 6.3.2 Cook Medical LLC
  • 6.3.3 B. Braun Melsungen AG
  • 6.3.4 Terumo Corporation
  • 6.3.5 Boston Scientific Corporation
  • 6.3.6 Medtronic plc
  • 6.3.7 Abbott Laboratories
  • 6.3.8 Teleflex Incorporated
  • 6.3.9 Atrion Corporation
  • 6.3.10 Argon Medical Devices Inc.
  • 6.3.11 Cordis (Cardinal Health)
  • 6.3.12 Penumbra Inc.
  • 6.3.13 Nipro Corporation
  • 6.3.14 Olympus Corporation
  • 6.3.15 Smiths Medical
  • 6.3.16 Shenzhen SCW Medicath Ltd.
  • 6.3.17 Lepu Medical Technology
  • 6.3.18 Integra LifeSciences
  • 6.3.19 Acandis GmbH

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-Need Assessment